Medical Gyeonggi e-News

[Meerecompany] A Goal to Become Number 1 in the Global Market with the Surgical Robot “Revo-i”

  • Name 관리자
  • Date 2021-12-24
  • Views 1083

▲Promotional Video

 


 

Meerecompany, with a Goal to Become Number 1 in the Global Market with the Surgical Robot “Revo-i”

 


 

                       * Photograph: HoKun Lee_Executive Vice Present

 

Please briefly describe Meerecompany.

Meerecompany was founded in 1984. Our products include semiconductor display equipment and 3D sensors, and we are currently the number one company in the global market share of edge grinders. Based on the goals of the past founder of contributing to the future growth engine and enhancing people’s health, Meerecompany started to work on surgical robots. After 10 years of research and development, the company obtained a manufacturing permit for surgical robots from the Ministry of Food and Drug Safety (MFDS) for the first time in Korea in 2017, and launched the surgical robot “Revo-i" in March 2018. Revo-i was designated as the Innovative Medical Device No. 10 from the MFDS in May 2021. The global surgical robot market, which stands at 6.7 billion dollars as of 2020, is expected to have a very bright future with an annual growth of 12% on average to reach 11.8 billion dollars by 2025.

 

What are some of the features and advantages of the surgical robot “Revo-i?”

The surgical robot Revo-i is used for laparoscopic surgeries and endoscopic surgeries, but can also be used for abdominal and thoracic surgeries, and in urology and obstetrics and gynecology departments. One of its greatest advantages is that it is possible to minimize bodily injuries during surgeries and decrease the risks by enhancing the accuracy and safety of surgery. With its advanced technology and possibilities to increase patient survival rates, reduce the amount of time needed for recovery after surgery, and decrease the risk of infections, Revo-i is also being used for complex soft tissue surgeries. In addition, Revo-i has a competitive edge over the product of Company A, the current leader in the world market, in terms of price, maintenance costs, component costs, and more. If the use of Revo-i is covered under health insurance, we strongly believe that our product will contribute to enhancing medical accessibility.

 

Can you tell us about your future business plans or plans to enter the global market?

Currently, our products are used for laparoscopic surgeries in Korean hospitals. We plan to provide continuous upgrades to Revo-i based on feedback from the medical staff and clinical trials, and strengthen our marketing strategies to expand our range of clients to tertiary hospitals or medium- to large-sized hospitals. Our company has recently entered into a business contract with a Russian buyer and so will enter the Russian market. Some of our other strategic markets that we plan on entering include Central Asian countries and Southeast Asian countries such as Vietnam and Indonesia. We will continue to strive for innovation and boldly invest in R&D to ensure world-class technology for the global market.

 

Photograph: Revo_Robotic Surgical System

 

[Homepage] https://www.meerecompany.com/en